Fractyl Health Inc. is a biotechnology company focused on developing advanced treatments for chronic metabolic and inflammatory diseases. The company's primary endeavor is to transform the treatment landscape of type 2 diabetes and related metabolic disorders by targeting the underlying causes rather than merely managing symptoms. Fractyl Health Inc. employs innovative procedural therapies designed to modify the anatomy and functioning of the gastrointestinal tract, potentially altering the disease course. The company's pioneering work significantly impacts the healthcare sector, particularly within gastrointestinal treatment and metabolic disease management arenas. This places Fractyl Health Inc. at the forefront of efforts to address the global epidemic of metabolic diseases, offering new therapeutic options that aim to improve patient outcomes while reducing long-term healthcare costs. Established with a vision to revolutionize metabolic disease treatment, Fractyl Health Inc. is involved in extensive research and clinical trials, underscoring its commitment to delivering breakthrough medical advancements.